New York, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the "Company"), announced today that an aggregate of $1,265,000 has been deposited into the Company's trust account for its public shareholders, representing $0.10 per public share, which enables the Company to extend the period of time it has to consummate its initial business combination by three months from October 29, 2022 to January 29, 2023 (the "Extension"). The Extension is the first of up to two three-month extensions permitted under the Company's governing documents.
About Deep Medicine Acquisition Corp.
DMAQ is a special purpose acquisition company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. DMAQ began trading on the Nasdaq in October 2021, and its common stock and rights are traded under the ticker symbols DMAQ and DMAQR, respectively.
Cautionary Note Regarding Forward-Looking Statements
This press release may include, and oral statements made from time to time by representatives of the Company may include, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the Securities and Exchange Commission ("SEC"). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact
Humphrey Polanen, Chief Executive Officer
Deep Medicine Acquisition Corp.
595 Madison Avenue, 12th Floor
New York, NY 10017
ir@dmaq-spac.com
Telephone: (917) 289-2776
ユニバーサル通信社ニューヨーク、2022年10月20日(ユニバーサル通信社)-深医薬買収会社(ナスダック株式コード:DMAQ)(以下、“会社”と略す)は今日、会社が公衆株式0.1ドルに相当する合計1,265,000ドルを会社の信託口座に入金し、初期業務合併完了期間を2022年10月29日から2023年1月29日まで3ヶ月延長することができると発表した(以下、“延展”と略す)。今回の延期は、同社の管理書類が許可した最大2回の3カ月延期の中で初めて。
について深深医薬買収会社。
DMAQは、1つまたは複数の企業またはエンティティとの合併、資本交換、資産買収、株式購入、再編、または他の同様の業務組み合わせのために設立された特別な目的買収会社である。帝馬Qは2021年10月にナスダックで取引を開始し、その普通株および権利はそれぞれDMAQおよびDMAQRの株式コードで取引される。
前向き陳述に関する注意事項
本プレスリリースには、会社代表が時々行った口頭声明には、改正された1933年証券法第27 A節と改正された1934年証券取引法第21 E節に示された“前向き声明”が含まれる可能性がある。本プレスリリースに含まれる可能性のある業務合併及びその融資及び関連事項に関する陳述、及び歴史的事実陳述以外のすべての陳述は前向き陳述である。本プレスリリースでは,“予想”,“信じる”,“継続”,“可能”,“推定”,“予想”,“予定”,“可能”,“可能”,“計画”,“可能”,“潜在”,“予測”,“計画”,“プロジェクト”,“すべき”,“会する”などの語彙と,我々や我々の管理チームに関する類似表現を用いて前向きな陳述である.これらの前向きな陳述は、経営陣の信念と、会社経営陣が行っている仮説と現在把握している情報に基づいている。会社が米国証券取引委員会(“米国証券取引委員会”)に提出した文書に詳述されているいくつかの要因により、実際の結果は前向き陳述で予想されていたものと大きく異なる可能性がある。私たちまたは私たちを代表する人に起因するすべての後続の書面または口頭前向き陳述は、この段落によって制限される。展望性陳述は多くの条件の制約を受け、その中の多くの条件は当社が米国証券取引委員会に提出した登録説明書と株式募集説明書のリスク要素の部分的に記載された条件を含む当社がコントロールできるものではない。法律の要件を除いて、当社は、本プレスリリースの日後にこれらの声明を更新して改訂または変更を行う義務を負いません。
連絡先
ハンフリー·ボラニン最高経営責任者
深深医薬買収会社。
マディソン通り595号、12階
ニューヨーク市、郵便番号:10017
メールボックス:ir@dmaq-space.com
電話:(917)289-2776